CUG 288
Alternative Names: CUG-288; TILKine™ 2Latest Information Update: 22 Apr 2022
At a glance
- Originator Cugene
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Apr 2022 Pharmacodynamics and adverse events data from preclinical trials in Solid tumours released by Cugene
- 20 Apr 2022 CUG 288 is available for licensing as of 20 Apr 2022. https://cugene.com/investors/
- 20 Apr 2022 Preclinical trials in Solid tumours in USA (Parenteral), prior to April 2022 (Cugene pipeline, April 2022)